Physician profile
Mohammad Hafeez
NPI 1639101595
$6,456.53
in general payments reported to CMS, 2019-2025
38 companies · $1,336 in 2025
The $1,336 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $296 · 2020: $690 · 2021: $870 · 2022: $920 · 2023: $1,022 · 2024: $1,323 · 2025: $1,336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,681.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,006.18 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $639.78 | 2020-2025 | Jardiance |
| Glaxosmithkline, LLC. | $606.13 | 2019-2025 | Trelegy Ellipta |
| Pfizer INC. | $536.14 | 2019-2025 | |
| Lilly USA, LLC | $533.00 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $432.28 | 2020-2025 | Xifaxan |
| Novo Nordisk INC | $385.82 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $272.12 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Sk Life Science, INC. | $257.69 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $229.02 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $209.40 | 2021-2024 | Xarelto |
| Abbvie INC. | $128.80 | 2021-2025 | |
| Eisai INC. | $115.90 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $112.69 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $111.76 | 2023-2025 | Xtampza |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Hafeez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.